IL1B and myocardial infarction: Apart from this strategy, intravenous anti-TNFα (etanercept, Adalimumab, Infliximab)31,32, anti-IL833,34 or anti-IL-1ß (canakinumab, gevokizumab)35–37 gene disruption or treatment are shown to reduce myocardial infarction (MI) in animal models, human patients or human cells38–41.